Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) - including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PM) - are clonal stem cell disorders characterized by acquired activating mutations which result in an excessive production of red blood cells, platelets, and neutrophils. Recent advances in the understanding of the molecular biology and genomics of MPNs have led to the development of novel targeted treatment approaches; however, the high rate of life-threatening vascular events and the high risk of disease progression with myelofibrotic and leukemic transformation continue to present challenges in the management of MPNs. Thereby, there remains a need for novel treatment strategies. Recently, research has revealed a role for clonal hematopoiesis, driver mutations and inflammation in thrombosis risk, which may provide a basis for novel thrombosis-prevention strategies.
With this Research Topic, we aim to collate new insights into the biology and disease mechanisms of MPNs and their potential consequences for diagnosis and treatment.
We welcome Original Research, Review and Mini-review articles related to, but not limited to, the following topics:
• Pathophysiology of MPN development
• Role of inflammation in disease initiation, development, symptomatology and progression
• Role of predisposing inherited genetic variation
• Molecular pathogenesis of thrombosis
• Utility of molecular markers in prognostication in MPN
• Novel therapeutic approaches and personalized medicine in MPN
Important note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Prof. Gabriela Baerlocher has previously undertaken consultancy work with Geron Corporation.
Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) - including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PM) - are clonal stem cell disorders characterized by acquired activating mutations which result in an excessive production of red blood cells, platelets, and neutrophils. Recent advances in the understanding of the molecular biology and genomics of MPNs have led to the development of novel targeted treatment approaches; however, the high rate of life-threatening vascular events and the high risk of disease progression with myelofibrotic and leukemic transformation continue to present challenges in the management of MPNs. Thereby, there remains a need for novel treatment strategies. Recently, research has revealed a role for clonal hematopoiesis, driver mutations and inflammation in thrombosis risk, which may provide a basis for novel thrombosis-prevention strategies.
With this Research Topic, we aim to collate new insights into the biology and disease mechanisms of MPNs and their potential consequences for diagnosis and treatment.
We welcome Original Research, Review and Mini-review articles related to, but not limited to, the following topics:
• Pathophysiology of MPN development
• Role of inflammation in disease initiation, development, symptomatology and progression
• Role of predisposing inherited genetic variation
• Molecular pathogenesis of thrombosis
• Utility of molecular markers in prognostication in MPN
• Novel therapeutic approaches and personalized medicine in MPN
Important note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Prof. Gabriela Baerlocher has previously undertaken consultancy work with Geron Corporation.
